Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

992 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S, Loi S, André F, Chandarlapaty S, Felip E, Finn SP, Jänne PA, Kerr KM, Munzone E, Passaro A, Pérol M, Smit EF, Swanton C, Viale G, Stahel RA. Peters S, et al. Among authors: viale g. Ann Oncol. 2024 Jul;35(7):607-629. doi: 10.1016/j.annonc.2024.04.002. Epub 2024 Apr 20. Ann Oncol. 2024. PMID: 38648979 Review.
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.
Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im YH, Huang CS, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Raimbault A, McConnell R, Monturus E, de Azambuja E, Gomez HL, Bliss J, Viale G, Bines J, Piccart M; APHINITY Steering Committee and Investigators. Loibl S, et al. Among authors: viale g. J Clin Oncol. 2024 Sep 11:JCO2302505. doi: 10.1200/JCO.23.02505. Online ahead of print. J Clin Oncol. 2024. PMID: 39259927
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.
Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G; International Breast Cancer Study Group. Ravaioli A, et al. Among authors: viale g. Ann Oncol. 2008 Apr;19(4):660-8. doi: 10.1093/annonc/mdm547. Epub 2008 Feb 13. Ann Oncol. 2008. PMID: 18272916 Free article. Clinical Trial.
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, Mittendorf EA, Schneider B, Prat A, Winer EP, Krop IE, Tolaney SM; Consortium of the TBCRC Translational Investigators; TBCRC Translational Investigators. Tarantino P, et al. J Clin Oncol. 2024 Jun 27:JCO2302170. doi: 10.1200/JCO.23.02170. Online ahead of print. J Clin Oncol. 2024. PMID: 38935923
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Pagani O, et al. Breast Cancer Res Treat. 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25. Breast Cancer Res Treat. 2009. PMID: 18953651 Free PMC article. Clinical Trial.
A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study.
DeCensi A, Bonanni B, Maisonneuve P, Serrano D, Omodei U, Varricchio C, Cazzaniga M, Lazzeroni M, Rotmensz N, Santillo B, Sideri M, Cassano E, Belloni C, Muraca M, Segnan N, Masullo P, Costa A, Monti N, Vella A, Bisanti L, D'Aiuto G, Veronesi U; Italian HOT Study Group. DeCensi A, et al. Ann Oncol. 2013 Nov;24(11):2753-60. doi: 10.1093/annonc/mdt244. Epub 2013 Jul 17. Ann Oncol. 2013. PMID: 23864098 Free article. Clinical Trial.
Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation.
Johansson H, Guerrieri-Gonzaga A, Gandini S, Bertelsen BE, Macis D, Serrano D, Mellgren G, Lazzeroni M, Thomas PS, Crew KD, Kumar NB, Briata IM, Galimberti V, Viale G, Vornik LA, Aristarco V, Buttiron Webber T, Spinaci S, Brown PH, Heckman-Stoddard BM, Szabo E, Bonanni B, DeCensi A. Johansson H, et al. Among authors: viale g. NPJ Breast Cancer. 2024 Jan 18;10(1):7. doi: 10.1038/s41523-024-00616-8. NPJ Breast Cancer. 2024. PMID: 38238336 Free PMC article.
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
Dugo M, Huang CS, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Antón-Torres A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Blasi O, Callari M, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Dugo M, et al. Among authors: viale g. Clin Cancer Res. 2024 Sep 23:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-0149. Online ahead of print. Clin Cancer Res. 2024. PMID: 39308141
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Baron-Hay S, Gión M, Guarneri V, Bianchini G, Wildiers H, Escrivá-de-Romaní S, Prahladan M, Bridge H, Kuptsova-Clarkson N, Scotto N, Verma S, Lin NU; DESTINY-Breast12 study group. Harbeck N, et al. Among authors: viale g. Nat Med. 2024 Sep 13. doi: 10.1038/s41591-024-03261-7. Online ahead of print. Nat Med. 2024. PMID: 39271844
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
O'Regan RM, Zhang Y, Fleming GF, Francis PA, Kammler R, Viale G, Dell'Orto P, Lang I, Bellet M, Bonnefoi HR, Tondini C, Villa F, Bernardo A, Ciruelos EM, Neven P, Karlsson P, Müller B, Jochum W, Zaman K, Martino S, Geyer CE Jr, Jerzak KJ, Davidson NE, Coleman RE, Ingle JN, van Mackelenbergh MT, Loi S, Colleoni M, Schnabel CA, Treuner K, Regan MM. O'Regan RM, et al. Among authors: viale g. JAMA Oncol. 2024 Aug 15:e243044. doi: 10.1001/jamaoncol.2024.3044. Online ahead of print. JAMA Oncol. 2024. PMID: 39145953
992 results